Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

Vaccine

Volumn 28, Issue 31, 2010, Pages 5023-5030

  Giuliani, Marzia M ^a   Biolchi, Alessia ^a   Serruto, Davide ^a   Ferlicca, Francesca ^a   Vienken, Kay ^b   Oster, Philipp ^a   Rappuoli, Rino ^a   Pizza, Mariagrazia ^a   Donnelly, John ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b GSK Marburg Vaccines and Diagnostics   (Germany)

Author keywords

MenB vaccine; Neisseria meningitidis; Serum bactericidal activity

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; CHLORAMPHENICOL; ERYTHROMYCIN; KANAMYCIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE VESICLE VACCINE; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; COMPLEMENT; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; IMMUNIZATION; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; TREATMENT OUTCOME; VACCINE PRODUCTION; ANIMAL; CLASSIFICATION; FEMALE; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS;

ANIMALS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINES, SYNTHETIC;

EID: 77954761297     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.014     Document Type: Article

References (34)

1. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969, 129(6):1327-1348.
2. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
3. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969, 129(6):1367-1384.
4. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969, 129(6):1385-1395.
5. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L. Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992, 10(10):691-698.
6. Ramsay M.E., Andrews N., Kaczmarski E.B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001, 357(9251):195-196.
7. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5(1):21-30.
8. Holst J., Feiring B., Fuglesang J.E., Hoiby E.A., Nokleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21(7-8):734-737.
9. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281(16):1520-1527.
10. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(17-18):2191-2196.
11. Wedege E., Bolstad K., Aase A., Herstad T.K., McCallum L., Rosenqvist E., et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 2007, 14(7):830-838.
12. Holst J., Feiring B., Naess L.M., Norheim G., Kristiansen P., Hoiby E.A., et al. The concept of " tailor-made" , protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23(17-18):2202-2205.
13. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(29):10834-10839.
14. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
15. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188(11):1730-1740.
16. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010, 107(8):3770-3775.
17. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
18. Beernink P.T., Granoff D.M. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008, 76(6):2568-2575.
19. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195(11):1445-1454.
20. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004, 72(7):4217-4223.
21. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
22. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(24):5093-5107.
23. Borrow R., Aaberge I.S., Santos G.F., Eudey T.L., Oster P., Glennie A., et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005, 12(8):970-976.
24. Giuliani M.M., Santini L., Brunelli B., Biolchi A., Arico B., Di Marcello F., et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 2005, 73(2):1151-1160.
25. Welsch J.A., Rossi R., Comanducci M., Granoff D.M. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 2004, 172(9):5606-5615.
26. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27(21):2794-2803.
27. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 2009, 47(11):3577-3585.
28. Jacobsson S., Hedberg S.T., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009, 27(10):1579-1584.
29. Jacobsson S., Thulin S., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006, 24(12):2161-2168.
30. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
31. Brehony C., Jolley K.A., Maiden M.C. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 2007, 31(1):15-26.
32. Drabick J.J., Brandt B.L., Moran E.E., Saunders N.B., Shoemaker D.R., Zollinger W.D. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 1999, 18(1-2):160-172.
33. Zollinger W.D., Moran E.E., Schmiel D.H. Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity. Clin Vaccine Immunol 2009, 16(12):1789-1795.
34. Minetti C.A.S.A., Tai J.Y., Blake M.S., Pullen J.K., Liang S.M., Remeta D.P. Structural and functional characterization of a recombinant PorB class 2 protein from Neisseria meningitidis: conformational stability and porin activity. J Biol Chem 1997, 272(16):10710-10720.